Surgery or High-Dose Radiation for Breast Cancer Survival

November 22, 2017

A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

  • Clinical Trial Information

    Trial Contact: Manchola-Orozco, Carolina

    Trial Phone: 321.841.7293

  • IRB No: NRG-BR002

    Protocol Abbrev: NRG-BR002

    Principal Investigator: Patrick Kelly, MD, PhD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: NRG-BR002

    Treatment: SBRT and surgical resection

    Therapies Involved: Chemotherapy ID: NCT02364557

  • Objective

    This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated.

  • Key Eligibility

    18 Years and older with Pathologically confirmed metastatic breast cancer within 270 days prior to registration